Symposium on Cardiovascular Regenerative Medicine

Welcome and Opening Remarks
Manfred Boehm, M.D.
National Heart, Lung, and Blood Institute

Keynote Address
Susan B. Shurin, M.D.
Acting Director
National Heart, Lung, and Blood Institute

NIH Center for Regenerative Medicine and Stem Cell Therapies
Mahendra S. Rao, M.D., Ph.D.
Director
NIH Center for Regenerative Medicine

Questions and Answers

Session I: New Advances in IPS-cell Technology
Moderator: Sean M. Wu, M.D., Ph.D.
                 Massachusetts General Hospital and Harvard Medical School

A Chemical Approach to Controlling Cell Fate
Sheng Ding, Ph.D.
Gladstone Institute of Cardiovascular Disease

Insights Into the Mechanisms Underlying iPSC Generation
Kathrin Plath, Ph.D.
University of California, Los Angeles, School of Medicine

Modified mRNA: A Powerful New Tool for Cardiovascular Research
Derrick J. Rossi, Ph.D.
Harvard Medical School

Session II: Reprogramming for Cardiovascular Regeneration
Moderator: Joseph C. Wu, M.D., Ph.D.
                 Stanford School of Medicine

Epigenetic Regulation of Cardiac Regeneration
W. Robb MacLellan, M.D.
University of California, Los Angeles, School of Medicine

Reprogramming Approaches for Cardiovascular Disease
Deepak Srivastava, M.D.
Gladstone Institute of Cardiovascular Disease and
University of California, San Francisco

Cardiogenesis from Pluripotent Human Stem Cells: Mechanisms and Applications
Charles E. Murry, Ph.D., M.D.
University of Washington

Session III: Stem Cells and in vitro Disease Modeling
Moderator: Deepak Srivastava, M.D.
                 Gladstone Institute of Cardiovascular Disease and University of California,
                 San Francisco

Capturing Disease Genomes in iPS Cells
George Q. Daley, M.D., Ph.D.
Children's Hospital Boston and Harvard Medical School

Pursuing Pluripotency
Ihor R. Lemischka, Ph.D.
Mount Sinai School of Medicine

Modeling Inherited Cardiogenic Disorders With Human Induced Pluripotent Stem Cells
Lior Gepstein, M.D., Ph.D.
Rappaport Institute (Israel)

miRNAs and Cellular Reprogramming
Edward E. Morrisey, Ph.D.
University of Pennsylvania School of Medicine

Networking Dinner at Tragara Ristorante (register and pay separately)

7:00 a.m.

Registration

8:00 - 10:15 a.m.

Session IV: Translating Stem Cell Biology Toward Therapy
Moderator: George Q. Daley, M.D., Ph.D.
                 Children's Hospital Boston and Harvard Medical School

Stromal Dynamics
David T. Scadden, M.D.
Harvard University and Massachusetts General Hospital

Clinical Hurdles of Pluripotent Stem Cell Therapy
Joseph C. Wu, M.D., Ph.D.
Stanford University School of Medicine

Enhancing Stem Cell Regenerative Potential in Aging and Transplantation
Amy Wagers, Ph.D.
Joslin Diabetes Center and Harvard University

Induced Pluripotent Stem Cell-based Disease Modeling and Small Molecule Screening
   Reveal Modulators of Intracellular Lipid Metabolism
Sean M. Wu, M.D., Ph.D.
Massachusetts General Hospital and Harvard Medical School

Human Embryonic Stem Cell-derived Cardiomyocytes for Heart Disease: In Vitro
   Characterization and Pre-clinical Results
Joseph Gold, Ph.D.
Geron Corporation

Questions and Answers

10:15 a.m.

Break

10:45 a.m. - 12:40 p.m.

Session V: Tissue Engineering
Moderator: W. Robb MacLellan, M.D.
                 University of California, Los Angeles, School of Medicine

Towards a Tissue Engineered Heart: The Sum Will Be Harder Than the Parts
Kevin Kit Parker, Ph.D.
Harvard University

First Human use of an Allogeneic, Tissue Engineered Vascular Graft
Todd McAllister, Ph.D.
St. Joseph's Translational Research Inistute and Cytograft Tissue and Engineering, Inc.

Myocardial Regeneration Through Tissue Engineering
Gordana Vunjak-Novakovic, Ph.D.
Columbia University

Highly Functional Stem Cell-derived Cardiac Tissues
Nenad Bursac, Ph.D.
Duke University

Questions and Answers

12:40 p.m.

Lunch

1:40 - 3:35 p.m.

Session VI: Update on NHLBI Progenitor Consortium
Moderator: Denis B. Buxton, Ph.D.
                 National Heart, Lung, and Blood Institute

Stem Cell Approaches To Understand Lung Injury Repair and Lung Cancers
Carla Kim, Ph.D.
Children’s Hospital Boston and Harvard Medical School

An ES/iPS Cell Strategy for Platelet Transfusions
Mortimer Poncz, M.D.
The Children’s Hospital of Philadelphia

Optimizing Cardiovascular Stem Cells for Cardiac Repair and Regeneration
Antonis Hatzopoulos, Ph.D.
Vanderbilt University

Epigenetic State and Genetic Stability of Human iPS Cells
James A. Thomson, V.M.D., Ph.D.
Morgridge Institute for Research and University of Wisconsin

Questions and Answers

3:35 - 4:50 p.m.

Session VII: Clinical Trials Update/Roundtable: Are we Ready for the Next Generation of Stem Cell-related Therapy?
Moderators: Jason C. Kovacic, M.D., Ph.D., F.A.C.C.
                   Mount Sinai Hospital

                   Sonia Skarlatos, Ph.D.
                   National Heart, Lung, and Blood Institute

Cardiosphere-derived Cells for Heart Regeneration: Proof of Concept in Humans
Eduardo Marbán, M.D., Ph.D.
Cedars-Sinai Medical Center

Progress and Perspectives From the NHLBI-sponsored Cardiovascular Cell Therapy
   Research Network
Robert D. Simari, M.D.
Mayo Clinic

Cell-based Therapy for Cardiac Repair: From Concept to Clinic
Joshua M. Hare, M.D.
University of Miami

Autologous CD34+ Cell Therapy for Ischemic Tissue Repair: Human Clinical Experience
Douglas W. Losordo, M.D.
Northwestern University/Northwestern Memorial Hospital

The BOOST Translational Study Program
Kai C. Wollert, M.D.
Hannover Medical School (Germany)

4:50 p.m.

Closing Remarks and Adjournment
Manfred Boehm, M.D.
National Heart, Lung, and Blood Institute